First-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (RR) acute myeloid leukemia (AML): Preliminary data.

被引：8
|
作者：
Borthakur, Gautam
Wolff, Johannes E.
Aldoss, Ibrahim
Hu, Beibei
Minh Dinh
Torres, Alison
Chen, Xiaotian
Rizzieri, David
Sood, Anjla
Odenike, Olatoyosi
Jonas, Brian Andrew
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] AbbVie Inc, N Chicago, IL USA
[3] Univ Calif, City Hope, Duarte, CA USA
[4] Duke Univ, Sch Med, Durham, NC USA
[5] Univ Chicago Med, Chicago, IL USA
[6] Univ Chicago, Comprehens Canc Ctr, Chicago, IL 60637 USA
[7] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA 95817 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.7019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7019
引用
收藏
页数：2
相关论文
共 22 条
  • [1] First-In-Human Study of ABBV-075 (Mivebresib), A Pan-Inhibitor of Bromodomain and Extra Terminal (BET) Proteins, in Patients (Pts) With Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML): Preliminary Data
    Borthakur, Gautam
    Wolff, Johannes
    Aldoss, Ibrahim
    Hu, Beibei
    Minh Dinh
    Torres, Alison
    Chen, Xiaotian
    Rizzieri, David
    Sood, Anjla
    Odenike, Olatoyosi
    Jonas, Brian A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S203 - S203
  • [2] Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute myeloid leukemia.
    Odenike, Olatoyosi
    Wolff, Johannes E.
    Borthakur, Gautam
    Aldoss, Ibrahim Taha
    Rizzieri, David
    Prebet, Thomas
    Hu, Beibei
    Minh Dinh
    Chen, Xiaotian
    Modi, Dimple
    Freise, Kevin J.
    Jonas, Brian Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
    Piha-Paul, Sarina A.
    Sachdev, Jasgit C.
    Barve, Minal
    LoRusso, Patricia
    Szmulewitz, Russell
    Patel, Sapna Pradyuman
    Lara, Primo N., Jr.
    Chen, Xiaotian
    Hu, Beibei
    Freise, Kevin J.
    Modi, Dimple
    Sood, Anjla
    Hutti, Jessica E.
    Wolff, Johannes
    O'Neil, Bert H.
    CLINICAL CANCER RESEARCH, 2019, 25 (21) : 6309 - 6319
  • [4] Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (R/R) solid tumors.
    Piha-Paul, Sarina Anne
    Sachdev, Jasgit C.
    Barve, Minal A.
    LoRusso, Patricia
    Szmulewitz, Russell Zelig
    Patel, Sapna Pradyuman
    McKee, Mark D.
    Wolff, Johannes E.
    Hu, Beibei
    Sood, Anjla
    Chen, Xiaotian
    Wilson, Sarah C.
    O'Neil, Bert H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia
    Borthakur, Gautam
    Odenike, Olatoyosi
    Aldoss, Ibrahim
    Rizzieri, David A.
    Prebet, Thomas
    Chen, Chris
    Popovic, Relja
    Modi, Dimple A.
    Joshi, Rujuta H.
    Wolff, Johannes E.
    Jonas, Brian A.
    CANCER, 2021, 127 (16) : 2943 - 2953
  • [6] Uveal melanoma patients (pts) treated with abbv-075 (mivebresib), a pan-inhibitor of bromodomain and extraterminal (BET) proteins: Results from a phase 1 study.
    Patel, Sapna Pradyuman
    Wolff, Johannes E.
    Mostorino, Rosa Margarita
    Chen, Xiaotian
    McKee, Mark D.
    Piha-Paul, Sarina Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.
    Wang, Judy Sing-Zan
    De Vita, Serena
    Karlix, Janet L.
    Cook, Carl
    Littlewood, Gillian M.
    Hattersley, Maureen M.
    Moorthy, Ganesh
    Edlund, Helena
    Fabbri, Giulia
    Sachsenmeier, Kris F.
    Davison, Chris
    Clark, Edwin
    Moore, Kathleen N.
    Bauer, Todd Michael
    Ulahannan, Susanna Varkey
    Patel, Manish R.
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] First-in- Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)
    de Jonge, Maja J. A.
    Carneiro, Benedito A.
    Devriese, Lot
    Doi, Toshihiko
    Penugonda, Sudhir
    Petrich, Adam M.
    Nuthalapati, Silpa
    Motwani, Monica
    Modi, Dimple A.
    Chang, Yu-Wei
    Calvo, Emiliano
    Moreno, Victor
    BLOOD, 2019, 134
  • [9] Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study.
    Watts, Justin M.
    Hunter, Anthony
    Iurlo, Alessandra
    Xicoy, Blanca
    Palandri, Francesca
    Reeves, Brandi
    Vannucchi, Alessandro M.
    Bose, Prithviraj
    Diaz, Rosa Ayala
    Halpern, Anna B.
    Chen, Xuejun
    Seguy, Francis
    Zhou, Feng
    Zheng, Fred
    Vachhani, Pankit
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] First-in-human study of FLX925, an orally administered FLT3/CDK4/CDK6 inhibitor, in subjects with relapsed or refractory acute myeloid leukemia (AML).
    Daver, Naval Guastad
    Konopleva, Marina
    Kohrt, Holbrook Edwin
    Fridman, Jordan Scott
    Johnson, Dan
    Jaen, Juan C.
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
123